BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35447134)

  • 21. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation sequencing identified somatic alterations that may underlie the etiology of Chinese papillary thyroid carcinoma.
    Yang C; Gong J; Xu W; Liu Z; Cui D
    Eur J Cancer Prev; 2023 May; 32(3):264-274. PubMed ID: 31724970
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
    Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
    Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Activating Mutations of the
    Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
    Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
    [No Abstract]   [Full Text] [Related]  

  • 27. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
    Moses W; Weng J; Kebebew E
    Thyroid; 2011 Apr; 21(4):367-71. PubMed ID: 21190444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
    Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
    Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
    Yang C; Xu W; Gong J; Liu Z; Cui D
    Cancer Biomark; 2020; 27(4):445-460. PubMed ID: 32065787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
    Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
    J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole Genome Sequencing Prioritizes
    Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
    Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.
    Song L; Wang X; Cheng W; Wu Y; Liu M; Liu R; Zhang S; Xia H; Liu H; Tai X; Zhao H; Li X; Ji F
    BMC Pulm Med; 2021 Dec; 21(1):420. PubMed ID: 34923982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.
    Liu C; Yu Y; Yin G; Zhang J; Wen W; Ruan X; Li D; Zhang S; Cai W; Gao M; Chen L
    Biochem Biophys Res Commun; 2017 Jan; 482(4):590-596. PubMed ID: 27864143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.